Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics gets approval for PQ Grass trial

Allergy Therapeutics has received approval for a phase II clinical trial of investigating the dosing of PQ Grass, an ultra-sho...

Approval for PQ Grass Phase II trial

RNS Number: 9660Q Allergy Therapeutics PLC 18 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Approval of clinical trial application for PQ Grass Phase II trial - Trial aimed at determining optimal dose of an MPL-adjuvanted, modified grass allergy vaccine - 18 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integra...

Allergy Therapeutics expands R&D and clinical team

Allergy Therapeutics has announced new senior appointments and expansion of the R&D and clinical team in line with th...

Expansion of Clinical Development and R&D teams

RNS Number: 2846Q Allergy Therapeutics PLC 11 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Expansion of Clinical Development and R&D teams - Key appointments reflect Group's commitment to EU and US strategy for product development - 11 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated special...

All News

DateHeadlineSource
27-06-17Investor and analyst site visitsRNS
19-06-17Allergy Therapeutics hosts satellite symposium at EAACIStockMarketWire
19-06-17Satellite Symposium at EAACI 2017RNS
06-06-17Directorate changesRNS
02-06-17Holding(s) in CompanyRNS
13-04-17Issue of EquityRNS
05-04-17Hardman Research: Development across portfolioRNS
04-04-17Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
29-03-17Interim Results for six months ended 31 Dec 2016RNS
16-03-17Allergy Therapeutics recruits first patient in birch pollen trial StockMarketWire
16-03-17First Patient in Pivotal Phase III Birch StudyRNS
09-03-17Notice of Interim ResultsRNS
14-02-17Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLCStockMarketWire
14-02-17Allergy Therapeutics vaccine gains CTA spprovalStockMarketWire
14-02-17House Dust Mite Allergy Vaccine Gains CTA ApprovalRNS
08-02-17Directorate ChangeRNS
01-02-17Allergy Therapeutics positive data in peanut allergy vaccineStockMarketWire
01-02-17Positive Efficacy & Safety Data in Peanut VaccineRNS
20-01-17Hardman Research: Investment driving market shareRNS
19-01-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
19-01-17Allergy Therapeutics revenues up StockMarketWire
19-01-17Trading UpdateRNS
09-01-17Top 10 small-cap share tips for 2017Interactive Investor
06-01-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
30-12-16Grant of AwardsRNS
25-11-16Allergy Therapeutics resolutions passed at AGMStockMarketWire
24-11-16Result of AGMRNS
02-11-16Allergy Therapeutics granted EU patent StockMarketWire
02-11-16EU Patent Office grants patent for MCTRNS
27-10-16Issue of equity in respect of exercise of optionsRNS
24-10-16Annual Report and AccountsRNS
14-10-16Share of the week: Tipped to double againInteractive Investor
10-10-16New data from novel adjuvant systemRNS
03-10-16Issue of equity in respect of exercise of optionsRNS
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory